ASCO 2020: Teresa's efficacy in early and mid-term NSCLC will be announced

As a detailed result of NSCLC-assisted therapy in Phase 3 clinical trialADAURA
the third generation of EGFR inhibitor Tagrisso has been used as a first-line therapy to demonstrate excellent efficacy in patients with metastatic NSCLC patients withEGFR mutationsAt this year's ASCO annual meeting, the company will announceTagrisso as an adjunct therapy, the efficacy of treatment in patients with NSCLC in stages IB, II and IIIAIn a randomized double-blind, placebo-controlled Phase 3 clinical trial called ADAURA, 682 Patients withEGFRmutations in NSCLC received Tagrisso or placebo-assisted treatment after a complete removal of the tumorThe main endpoint of the trial was disease-free survival (DFS)AstraZeneca announced in early April that the trial had been terminated prematurely because of the significant and clinical benefits that Tagrisso had shownIt is worth noting thatthe original trial is expected to end in 2022, the ability to terminate the trial two years early raised expectations of Tagrisso's efficacyAstraZeneca said it had begun filing regulatory applications that, if approved, would significantly expand Tagrisso's patient baseThe main study endpoint of the ADAURA III trial was Disease-Free Survival (DFS), which evaluated Terisa's three-year treatment with a placeboThe trial will continue to evaluate the secondary endpoints of the total lifetime In its communication with AstraZeneca, IDMC did not raise any new security-related issues Data will be published on assoonth ASCO 2020
author: MedSci Source: MedSci Original